ICU sedation, delirium & recovery
Furosemide with adjunctive acetazolamide vs furosemide only in critically ill patients: A pilot two-center randomized controlled trial
Authors' conclusion
Adjunctive acetazolamide may increase diuretic efficacy and counterbalance furosemide-induced metabolic alkalosis without safety concerns.
Study context
- Population
- Intensive care units (ICU) patients for whom treating physicians planned IV diuretic therapy
- Participants
- 15 vs 15
- Comparison
- Furosemide plus adjunctive acetazolamide vs furosemide alone
- Furosemide + acetazolamiden = 15
- Furosemide alonen = 15reference
- Primary endpoint
- Urine output
- Follow-up
- First six hours
Methodological detailspilot, two-center, open-label, Bayesian framework
- Pilot
- Two-center
- Open-label
- Bayesian framework
Primary result
As reported in the abstract
- Adjunctive acetazolamide didn't increase urine output in the first six hours
- Bayesian analysis; CrI
Further findings
| Outcome | Estimate | |
|---|---|---|
| Plasma pH · six hours>95 % probability · CrI | pH difference −0.045 (CrI [−0.081, −0.008]) | |
| Urine pH · six hours>95 % probability · CrI | difference 1.10 (CrI [0.04, 2.11]) | |
| −10123Difference (linear scale) |
Urine output response to furosemide · 24 h
- Greater urine output response with adjunctive acetazolamide vs furosemide alone
- 100 % probability
Safety
Severe acidosis or electrolyte disturbances · 24 h
- No severe acidosis or electrolyte disturbances observed
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Furosemide with adjunctive acetazolamide vs furosemide only in critically ill patients: A pilot two-center randomized controlled trial. J Crit Care. Published 16 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →